“Safety of Abrocitinib in 3582 Patients With Moderate-to-Severe Atopic Dermatitis With Over 900 Patients Exposed for Almost 2 Years”. 2023. SKIN The Journal of Cutaneous Medicine 7 (2): s150. https://doi.org/10.25251/skin.7.supp.150.